Based on this single-arm trial of ketoconazole in six patients with adult granulosa cell tumor, only three of whom were confirmed to have the somatic FOXL2 mutation, ketoconazole achieved stable disease in five patients and was granted an orphan designation for this indication by the European Medicines Agency. Here, FOXL2 is linked to granulosa cell tumor.